
TY  - JOUR
TI  - Posters
JO  - Transplant International
JA  - Transpl Int
VL  - 30
IS  - S2
SN  - 0934-0874
UR  - https://doi.org/10.1111/tri.13053
DO  - doi:10.1111/tri.13053
SP  - 390
EP  - 576
PY  - 2017
ER  - 

TY  - JOUR
TI  - Poster
JO  - Transplant International
JA  - Transpl Int
VL  - 26
IS  - s1
SN  - 0934-0874
UR  - https://doi.org/10.1111/tri.12181
DO  - doi:10.1111/tri.12181
SP  - 28
EP  - 57
PY  - 2013
ER  - 

TY  - JOUR
TI  - Posters
JO  - Basic & Clinical Pharmacology & Toxicology
VL  - 105
IS  - s1
SN  - 1742-7835
UR  - https://doi.org/10.1111/j.1742-7843.2009.00437.x
DO  - doi:10.1111/j.1742-7843.2009.00437.x
SP  - 44
EP  - 150
PY  - 2009
ER  - 

AU  - Dutta, Anand S.
C7  - pp. 1-80
TI  - Discovery of New Medicines
SN  - 9781405180351
UR  - https://doi.org/10.1002/9781444317800.ch1
DO  - doi:10.1002/9781444317800.ch1
SP  - 1-80
KW  - discovery of new medicines
KW  - understanding disease processes and mechanisms in controlling disease
KW  - severe acute respiratory syndrome (SARS)
KW  - new infectious diseases - hepatitis C, human herpes virus-6, -7 and -8 and bird flu (H5N1 virus)
KW  - underlying causes of diseases - selective and less toxic drugs
KW  - market needs and changing disease patterns
KW  - new technology impact on drug discovery
KW  - combinatorial chemistry and high-throughput screening
KW  - enzymes and enzyme inhibitors
KW  - DNA and RNA based therapeutics
PY  - 2009
AB  - Summary This chapter contains sections titled: Introduction Market needs and changing disease patterns Medicines marketed in the years 2004?2007 Historical aspects Impact of new technology on drug discovery Examples of drug discovery Enzymes and enzyme inhibitors Protein?protein interaction inhibitors Protein antibody and vaccine therapeutics DNA and RNA based therapeutics Conclusions References
ER  - 

C7  - pp. 719-777
TI  - Malaria and Babesiosis
SN  - 9781555818999
UR  - https://doi.org/10.1128/9781555819002.ch26
DO  - doi:10.1128/9781555819002.ch26
SP  - 719-777
KW  - clinical disease symptoms
KW  - disease prevention
KW  - disease treatment
KW  - epidemiologic studies
KW  - human babesiosis
KW  - laboratory diagnosis
KW  - life cycle
KW  - malaria infection
KW  - morphological identification
PY  - 2009
AB  - Summary Malaria Babesiosis
ER  - 

TY  - JOUR
TI  - ARA Scientific Posters
JO  - Internal Medicine Journal
VL  - 40
IS  - s3
SN  - 9781555818999
UR  - https://doi.org/10.1111/j.1445-5994.2010.02235_1.x
DO  - doi:10.1111/j.1445-5994.2010.02235_1.x
SP  - 5
EP  - 36
PY  - 2010
ER  - 

TY  - JOUR
TI  - Abstract
JO  - Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
VL  - 22
IS  - 3
SN  - 9781555818999
UR  - https://doi.org/10.1592/phco.22.5.403.33194
DO  - doi:10.1592/phco.22.5.403.33194
SP  - 403
EP  - 432
PY  - 2002
ER  - 

TY  - JOUR
TI  - E-Poster
JO  - Transplant International
JA  - Transpl Int
VL  - 32
IS  - S2
SN  - 9781555818999
UR  - https://doi.org/10.1111/tri.13512
DO  - doi:10.1111/tri.13512
SP  - 320
EP  - 399
PY  - 2019
ER  - 

TY  - JOUR
TI  - SAEM Annual Meeting Abstracts
JO  - Academic Emergency Medicine
JA  - Acad Emerg Med
VL  - 20
IS  - s1
SN  - 9781555818999
UR  - https://doi.org/10.1111/acem.12115
DO  - doi:10.1111/acem.12115
SP  - S4
EP  - S336
PY  - 2013
ER  - 

TY  - JOUR
TI  - Molecular biology of human genetic disease
JO  - Journal of Cellular Biochemistry
JA  - J. Cell. Biochem.
VL  - 56
IS  - S18A
SN  - 9781555818999
UR  - https://doi.org/10.1002/jcb.240560507
DO  - doi:10.1002/jcb.240560507
SP  - 183
EP  - 212
PY  - 1994
ER  - 

TY  - JOUR
AU  - Hall, H. Roe Bartle
TI  - ACCP 1999 Annual Meeting Abstracts
JO  - Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
VL  - 19
IS  - 10
SN  - 9781555818999
UR  - https://doi.org/10.1592/phco.19.15.1191.30577
DO  - doi:10.1592/phco.19.15.1191.30577
SP  - 1191
EP  - 1240
PY  - 1999
ER  - 

TY  - JOUR
TI  - Conference Program
JO  - Medical Physics
JA  - Med. Phys.
VL  - 46
IS  - 6
SN  - 9781555818999
UR  - https://doi.org/10.1002/mp.13596
DO  - doi:10.1002/mp.13596
SP  - 2782
EP  - 2883
PY  - 2019
ER  - 

TY  - JOUR
TI  - Abstracts
JO  - Alcoholism: Clinical and Experimental Research
JA  - Alcoholism: Clinical and Experimental Research
VL  - 28
IS  - S5
SN  - 9781555818999
UR  - https://doi.org/10.1111/j.1530-0277.2004.tb00028.x
DO  - doi:10.1111/j.1530-0277.2004.tb00028.x
SP  - 7A
EP  - 199A
PY  - 2004
ER  - 

TY  - JOUR
TI  - Abstract Supplement 2019 ACR/ARP Annual Meeting
JO  - Arthritis & Rheumatology
JA  - Arthritis Rheumatol
VL  - 71
IS  - S10
SN  - 9781555818999
UR  - https://doi.org/10.1002/art.41108
DO  - doi:10.1002/art.41108
SP  - 1
EP  - 5420
PY  - 2019
AB  - Abstract For a searchable version of these abstracts, please visit www.acrabstracts.org.
ER  - 

TY  - JOUR
TI  - Abstracts-Symposia
JO  - Alcoholism: Clinical and Experimental Research
JA  - Alcohol Clin Exp Res
VL  - 38
IS  - s1
SN  - 9781555818999
UR  - https://doi.org/10.1111/acer.12452
DO  - doi:10.1111/acer.12452
SP  - 293A
EP  - 359A
PY  - 2014
ER  - 

TY  - JOUR
TI  - Abstracts-part IV (Continue in Part V)
JO  - Proceedings of the International Society for Magnetic Resonance in Medicine
JA  - Proc. Soc. Magn. Reson. Med.
VL  - 1994
IS  - S1
SN  - 9781555818999
UR  - https://doi.org/10.1002/mrmp.22419940106
DO  - doi:10.1002/mrmp.22419940106
SP  - 201
EP  - 250
PY  - 1994
ER  - 

TY  - JOUR
TI  - ASBMR 18th Annual Meeting
JO  - Journal of Bone and Mineral Research
JA  - J Bone Miner Res
VL  - 11
IS  - S1
SN  - 9781555818999
UR  - https://doi.org/10.1002/jbmr.5650111202
DO  - doi:10.1002/jbmr.5650111202
SP  - S1
EP  - S500
PY  - 1996
ER  - 

TY  - JOUR
TI  - R1885 - R2270
JO  - Clinical Microbiology and Infection
VL  - 12
IS  - s4
SN  - 9781555818999
UR  - https://doi.org/10.1111/j.1470-9465.2006.12_4_1432.x
DO  - doi:10.1111/j.1470-9465.2006.12_4_1432.x
PY  - 2006
ER  - 

AU  - Razin, Shmuel
TI  - Mycoplasma
SN  - 9780470686386
UR  - https://doi.org/10.1002/9780470688618.taw0077
DO  - doi:10.1002/9780470688618.taw0077
KW  - Mycoplasma
KW  - Mycoplasmas-phenotypically distinguished by minute size and total lack of cell wall
KW  - mycoplasma-like organisms (MLO)
KW  - cellular morphology and cytoskeletal elements
KW  - cocultivation with cell cultures
KW  - mycoplasmas infecting cell cultures
KW  - intraspecies genetic heterogeneity
KW  - proteome and transcriptome analyses and bioinformatics
PY  - 2006
AB  - Abstract
ER  - 

AU  - MÃ¼ller, Lutz
AU  - Husar, Elisabeth
C7  - pp. 42-81
TI  - Preclinical Safety Testing
SN  - 9780470659878
UR  - https://doi.org/10.1002/9781118532331.ch3
DO  - doi:10.1002/9781118532331.ch3
SP  - 42-81
KW  - toxicity testing of pharmaceuticals
KW  - biologics
KW  - safety pharmacology
KW  - genetic toxicology
KW  - reproductive toxicity
KW  - carcinogenicity
KW  - impurities
KW  - juvenile toxicity
PY  - 2006
AB  - Summary Comprehensive preclinical safety testing in vitro and in animal models is mandatory when developing a potential new pharmaceutical compound. The primary objectives of such studies are to demonstrate that, under the conditions of human volunteer profiling and in therapy, the potential new drug is safe or its side effects can be monitored and managed. Hence, regulatory agencies need to be assured that the benefits of a new medicine outweigh the risks of therapy. Toxicologists have to assist clinicians in determining the likely range of safe exposures to the new pharmaceutical in appropriate animal and in vitro models and the possible consequences if these doses are exceeded. Early response surrogate biomarkers for toxicity can indicate when safety limits have been breached, but before significant damage has occurred. The chapter on preclinical safety describes the necessary experiments, their design and conduct versus the background of regulatory guideline expectations. The chapter also comprises expectations for animal safety testing of biologics, juvenile toxicity and describes new challenges for non-clinical safety studies such as the use of pluripotent stem cells.
ER  - 
